Alpha Tau’s latest brain-cancer progress may be the headline, but the bigger story is breadth: five oncology programs, FDA breakthrough designations, a pivotal skin-cancer trial, ASCO pancreatic data, and a major prostate partner backing the platform.
Glioblastoma is the most aggressive form of brain cancer. Once it returns after initial treatment, options run short and survival is usually measured in months. So when a small company’s experimental therapy controlled the disease in all three of the first patients it treated, and cleared the visible tumor entirely in two of them, doctors pushed to keep treating patients. On June 11, after reviewing the interim safety data, the U.S. Food and Drug Administration cleared Alpha Tau Medical Ltd. (NASDAQ: DRTS) to finish enrolling its U.S. brain-cancer trial. And brain cancer is only one of the cancers this company is going after.
That breadth is the part of the story that is easy to miss. Alpha Tau’s therapy, called Alpha DaRT, uses a single approach to attack many different solid tumors, and the company is running several programs at once. It holds FDA Breakthrough Device Designation for recurrent glioblastoma and for squamous cell carcinoma of the skin and oral cavity. Its first U.S. pivotal trial, in a recurrent skin cancer called cutaneous squamous cell carcinoma, finished enrolling in May, and the company has been submitting parts of its FDA application throughout the year on a rolling basis. It presented survival data from its pancreatic-cancer studies at this year’s ASCO meeting, and it has a head and neck program in the clinic. For a developer this size, that means the company is not riding on any single trial.
Unlike conventional radiation, which is typically beamed in from outside the body, Alpha DaRT works from inside it. Tiny radium-224 sources are placed directly inside a tumor, and as the radium decays it releases short-range alpha particles that damage nearby cancer cells, while the alpha-emitting atoms diffuse only a short distance, sparing much of the surrounding healthy tissue. The dose is concentrated where the sources sit, and the treatment is given in a single procedure rather than the repeated sessions conventional radiation usually requires.
The brain-cancer program, called REGAIN, is what just advanced. Roughly 14,000 Americans are diagnosed with glioblastoma each year, and once it recurs the options thin out fast. After reviewing a planned interim safety report on the first three patients, treated at The Ohio State University Comprehensive Cancer Center between December 2025 and March 2026, the FDA cleared Alpha Tau to enroll the remaining seven, up to ten in all, and approved two more U.S. academic centers as sites. As of the May 3 cutoff, all three patients had their disease controlled at the treated site and two had no visible tumor left on their scans, with a single treatment-related serious side effect that resolved. These are early results in only three patients in a trial built to test safety and feasibility, but they are encouraging, especially in a cancer where treatment options after recurrence are limited and historical response rates to commonly used therapies have generally been modest. Alpha DaRT has held FDA Breakthrough Device Designation in recurrent glioblastoma since 2021 and was taken into the agency’s Total Product Life Cycle Advisory Program, a selective track for promising devices, in 2024.
The newest of the company’s programs just drew a commercial partner. On June 3, Alpha Tau gave Tolmar International, a U.S. specialist in urology and oncology, exclusive rights to commercialize Alpha DaRT for prostate cancer in the United States once it is approved. Tolmar put up an initial $15 million to expand Alpha Tau’s manufacturing, made a $20 million equity investment at a 25% premium to the recent share price, and agreed to as much as $161.5 million in milestone payments, with Alpha Tau keeping 60% of net sales and Tolmar handling commercialization. A 20-year commitment of that size, with cash paid in at a premium, is a substantial outside commitment to the technology.
None of this guarantees an outcome. The brain-cancer trial still has to enroll and follow its remaining patients, and the prostate program is years from any approval. But a company that just had the FDA clear its next brain-cancer step, drew a partner to a second tumor, and has several more programs moving behind it holds more shots on goal than most developers its size. For a small-cap in oncology, that is an unusually full set of programs to have advancing at once.
Subscribe for Similar Reports
Read More from The Finance Herald
- Comstock’s SOCAR Plan Turns Haynesville Stakes Into Balance-Sheet Room
- GH Power Is Already Building for the AI Power Shortfall PJM Just Priced at Cap
- SEC-FDA Data Pact Tightens the Disclosure Test for Life-Sciences Companies
- Star Entertainment’s Smaller Loss Leaves Cash as the Real Turnaround Test
- Washington’s Yen Move Tests the Trust Behind Global Financial Stability
- Gap’s 13% Rally Puts Old Navy at the Center of Its Turnaround Test
- Apollo’s Atlantic Aviation Deal Reprices Private-Jet Infrastructure
- Nvidia’s 70% Growth Forecast Turns the AI Boom Into a Supply-Chain Test
- Canada’s Counter-Tariffs Raise the Price of Defending an Integrated Economy
- RBA’s August Pause Leaves Australia’s Next Rate Move Unsettled
Important Disclaimers and Disclosures: The author, Wall Street Wire, is a content and media technology platform that connects the market with under-the-radar companies. The platform operates a network of industry-focused media channels spanning finance, biopharma, cyber, AI, and additional sectors, delivering insights on both broader market developments and emerging or overlooked companies. Wall Street Wire is not a broker-dealer or investment adviser. References to market size estimates, valuations, price targets, or other third-party data are provided strictly for informational purposes. Wall Street Wire receives cash compensation on behalf of Alpha Tau Medical Ltd. (the “Issuer”) for coverage and awareness services, which are provided on an ongoing subscription basis. The content above is a form of paid advertising and promotion and is for informational purposes only and does not constitute financial or investment advice. This article may contain forward-looking statements about the Issuer’s products, plans, or prospects that are subject to risks and uncertainties; actual results may differ materially, and readers should review the Issuer’s public filings on SEC EDGAR (sec.gov/edgar) for full risk factors. Market size figures, research estimates, or other third-party data referenced in this article are quoted from publicly available sources believed to be reliable; however, we do not independently verify or endorse them, and additional figures or estimates may exist. Full compensation details, information about the operator of Wall Street Wire, and the complete set of disclaimers and disclosures applicable to this content are available at: wallstwire.ai/disclosures. This article should not be considered an official communication of the Issuer.